ARGOBIO
VC Fund
Paris, France
Argobio is a start-up studio devoted to developing unique therapeutic solutions, with the purpose of nurturing and launching revolutionary biotech firms. It sources cutting-edge early-stage projects from leading European academic research institutes in order to cultivate and nurture these projects before launching companies. The main focus is onrare diseases, neurological issues, oncology, and immunology. Additionally, the studio is looking to create promising platform technologies for therapeutic products.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries ARGOBIO invests in
Stages ARGOBIO invests in
Countries ARGOBIO invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Medical 3 (75%)
- Biotechnology 3 (75%)
- Health Care 2 (50%)
- Therapeutics 1 (25%)
Country
- France 2 (50%)
- The Netherlands 1 (25%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Daniel Sobral
Partner and Chief Financial Officer
|
Partner and Chief Financial Officer | Total investments: 0 | Find email | |
Neill Moray Mackenzie
Founding Partner and Entrepreneur in Residence
|
Founding Partner and Entrepreneur in Residence | Total investments: 0 | Find email | |
Poul Sørensen
Partner and Entrepreneur-in-Residence
|
Partner and Entrepreneur-in-Residence | Total investments: 0 | Find email | |
Remi Soula
Founding Partner, Entrepreneur in Residence
|
Founding Partner, Entrepreneur in Residence | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders. | $6.4M / Seed / Mar 23, 2026 | ||
| Enodia Therapeutics is a biotech company that provides transforming treatments for cancer, inflammation, and viral infection diseases. | $24.2M / Seed / Jan 08, 2026 | ||
| Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders. | $13.4M / Seed / Dec 03, 2025 | ||
| Elkedonia is a biotech company dedicated to transforming antidepressant therapy. It aims to develop a groundbreaking antidepressant treatment that is accessible, fast-acting, and free from the risks of dependence, sedation, or psychotic effects. | $12.9M / Seed / Jun 11, 2025 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does ARGOBIO invest in?
ARGOBIO invests primarily in Medical, Biotechnology and Health Care startups, most often at Seed stage. Most of the 4 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact ARGOBIO?
Public channels for ARGOBIO include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at ARGOBIO?
The team at ARGOBIO includes Daniel Sobral (Partner and Chief Financial Officer), Neill Moray Mackenzie (Founding Partner and Entrepreneur in Residence) and Poul Sørensen (Partner and Entrepreneur-in-Residence). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
